Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

3.090 -0.230 (-6.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
Via Benzinga
Omeros Corporation Reports First Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
From Omeros Corporation
Via Business Wire
What's Next: Omeros's Earnings Preview
Via Benzinga
Earnings Scheduled For May 15, 2025
Via Benzinga
Examining the Future: Omeros's Earnings Outlook
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Which stocks are moving on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
From Omeros Corporation
Via Business Wire
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
From Omeros Corporation
Via Business Wire
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
From Omeros Corporation
Via Business Wire
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
From Omeros Corporation
Via Business Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
From Omeros Corporation
Via Business Wire
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings
Via Benzinga
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
From Omeros Corporation
Via Business Wire
Earnings Scheduled For March 31, 2025
Via Benzinga
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
From Omeros Corporation
Via Business Wire
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
From Omeros Corporation
Via Business Wire
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
From Omeros Corporation
Via Business Wire
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
From Omeros Corporation
Via Business Wire
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.